Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Foti (Polygonum multiflorum) is a traditional Chinese herb containing stilbene compounds like 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG). It works primarily through antioxidant pathways and hepatoprotective mechanisms involving NF-κB modulation.
Origin & History
Fo-ti (He shou wu) is the root and rhizome of Polygonum multiflorum (now Pleuropterus multiflorus), a perennial climbing vine native to central and southern China, Japan, Taiwan, and Vietnam. The roots are harvested from 3-4 year-old plants and used either unprocessed ('white' fo-ti) or processed by steaming in black soybean juice to create 'red' fo-ti.
Research Narrative (Provisional)
High-quality human studies supporting fo-ti for any condition are lacking. Early research suggests a combination decoction containing fo-ti may help with hepatitis B-associated liver fibrosis, though the small amount of available research prevents firm conclusions. No PubMed-indexed randomized controlled trials or meta-analyses specific to fo-ti monotherapy were identified.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Foti (Polygonum multiflorum) root is not consumed as a macronutrient food source; its nutritional relevance lies primarily in its bioactive phytochemical content rather than conventional macronutrients or micronutrients. Dried root preparations contain approximately 70-80% carbohydrates by dry weight, primarily in the form of starch and structural polysaccharides (notably beta-1,3-glucans and rhamnogalacturonans at roughly 1.8-2.5% of dry weight). Protein content is low at approximately 3-5% dry weight, and fat content is negligible at under 1%. Crude fiber content is approximately 10-15% dry weight. The pharmacologically significant bioactive compounds include: (1) Stilbenes — trans-resveratrol (0.002-0.05% dry weight) and its glycoside piceid; (2) Stilbene glycosides — 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside (TSG), considered the primary marker compound, present at approximately 1.0-2.5% in raw root and up to 0.7-1.5% in processed (Zhi He Shou Wu) root per Chinese Pharmacopoeia standards (minimum 1.0% TSG required); (3) Anthraquinones — emodin (0.1-0.3% dry weight), physcion, rhein, and chrysophanol, which are substantially reduced upon processing with black bean decoction; (4) Tannins — predominantly condensed procyanidin B-type oligomers and polymeric tannins (5-8% dry weight), which contribute significantly to antioxidant activity; (5) Flavonoids — quercetin, kaempferol, and catechin derivatives at approximately 0.05-0.2% combined; (6) Phenolic acids — protocatechuic acid and gallic acid at trace to minor concentrations (0.01-0.05%). Processing (steaming with black bean liquid) significantly alters the phytochemical profile: free anthraquinone content drops by approximately 60-80%, reducing hepatotoxic risk, while TSG content may concentrate relatively. Mineral content includes modest levels of zinc (approximately 15-25 mg/kg dry weight), iron (approximately 80-120 mg/kg), calcium (approximately 400-600 mg/kg), and manganese (approximately 10-20 mg/kg), though these are not clinically meaningful at typical supplemental doses. Bioavailability of TSG is moderate, with animal studies suggesting oral bioavailability of approximately 20-35% with rapid hepatic metabolism; emodin undergoes extensive first-pass metabolism. Fat-soluble compounds such as resveratrol have improved absorption when taken with dietary fat.
Reported Mechanism (Provisional)
Foti's primary bioactive compound TSG (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) inhibits NF-κB signaling pathways, reducing inflammatory cytokine production. The stilbene compounds also activate Nrf2 pathways, enhancing cellular antioxidant defense systems. Additionally, emodin and other anthraquinones may contribute to hepatoprotective effects through modulation of liver enzyme activity.
Clinical Narrative (Provisional)
Human clinical evidence for foti remains limited, with most positive results coming from combination formulas rather than isolated foti studies. Small preliminary trials in hepatitis B patients showed potential liver function improvements, but sample sizes were under 100 participants. Animal studies demonstrate anti-atherosclerotic effects and improved lipid profiles, but these findings lack human validation. The majority of research consists of in vitro studies showing antioxidant activity, which cannot be directly extrapolated to human health outcomes.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.